Nasus Pharma Ltd
NSRX5.440USD
-0.280-4.83%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
49.28MValor de mercado
PerdaP/L TTM
Mais detalhes de Nasus Pharma Ltd Empresa
Nasus Pharma Ltd is an Israel-based pharmaceutical company. The Company conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The Company's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.
Informações de Nasus Pharma Ltd
Código da empresaNSRX
Nome da EmpresaNasus Pharma Ltd
Data de listagemAug 13, 2025
CEOTeleman (Dan)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 13
EndereçoYigal Alon 65
CidadeTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísIsrael
Código postal- -
Telefone97237326616
Sitehttps://www.nasuspharma.com
Código da empresaNSRX
Data de listagemAug 13, 2025
CEOTeleman (Dan)
Executivos da empresa Nasus Pharma Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+55292.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+42854.00%
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Mr. Ronnie Hershman
Mr. Ronnie Hershman
Independent Director
Independent Director
--
--
Mr. David Silberman, CPA
Mr. David Silberman, CPA
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Sharon Shacham, Ph.D.
Dr. Sharon Shacham, Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Isaac Israel
Isaac Israel
Independent Director Nominee
Independent Director Nominee
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Udi Gilboa
Mr. Udi Gilboa
Co-Founder, Executive Chairman of the Board of Director
Co-Founder, Executive Chairman of the Board of Director
1.90M
+55292.00%
Dr. Dalia Megiddo
Dr. Dalia Megiddo
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
Co-Founder, Director, Chief Development Officer and Chief Medical Officer
1.89M
+42854.00%
Mr. Dan Teleman
Mr. Dan Teleman
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Tair Lapidot, Ph.D.
Dr. Tair Lapidot, Ph.D.
Vice President of Research and Development and Clinical Development
Vice President of Research and Development and Clinical Development
--
--
Galia Temtsin Kryaz
Galia Temtsin Kryaz
Director of CMC and Product Development
Director of CMC and Product Development
--
--
Mr. Oren Elmaliach
Mr. Oren Elmaliach
Director of Finance
Director of Finance
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Outro
36.92%
Investidores
Investidores
Proporção
Gilboa (Udi)
21.09%
Megiddo (Dalia)
20.96%
Hershman Holdings L.L.C.
9.89%
Capital Point Ltd
6.38%
Phoenix Solutions Ltd
4.76%
Outro
36.92%
Tipos de investidores
Investidores
Proporção
Individual Investor
43.95%
Corporation
21.03%
Investment Advisor
0.03%
Outro
34.99%
Participação acionária institucional
Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
2
3.24K
0.00%
--
2025Q4
2
2.38K
0.03%
+1.14K
2025Q3
7
5.35M
59.33%
+5.35M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Gilboa (Udi)
1.90M
21.09%
+55.29K
+3.00%
Sep 30, 2025
Megiddo (Dalia)
1.89M
20.96%
+42.85K
+2.32%
Sep 30, 2025
Hershman Holdings L.L.C.
891.19K
9.89%
+414.18K
+86.83%
Sep 30, 2025
Capital Point Ltd
575.13K
6.38%
+575.13K
--
Aug 14, 2025
Phoenix Solutions Ltd
429.31K
4.76%
--
--
Sep 30, 2025
Krayz (Galia Temtsin)
171.72K
1.91%
+171.72K
--
Aug 12, 2025
Morgan Stanley Smith Barney LLC
2.00K
0.02%
+2.00K
--
Sep 30, 2025
UBS Financial Services, Inc.
1.24K
0.01%
+1.24K
--
Sep 30, 2025
Lapidot (Tair Ph.D.)
10.00
0%
+10.00
--
Aug 12, 2025
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
